The antiviral effects of RSV fusion inhibitor MDT‐637 on clinical isolates vs its achievable concentrations in the human respiratory tract and comparison to ribavirin

摘要

BackgroundRespiratory syncytial virus (RSV) viral load and disease severity associate, and the timing of viral load and disease run in parallel. An antiviral must be broadly effective against the natural spectrum of RSV genotypes and must attain concentrations capable of inhibiting viral replication within the human respiratory tract.